Longeveron (LGVN) Set to Announce Quarterly Earnings on Tuesday

Longeveron (NASDAQ:LGVN) is set to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Longeveron (NASDAQ:LGVN) last released its earnings results on Wednesday, August 14th. The company reported ($1.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.80). The company had revenue of $0.47 million during the quarter, compared to the consensus estimate of $0.53 million. Longeveron had a negative net margin of 1,513.83% and a negative return on equity of 237.57%. On average, analysts expect Longeveron to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Longeveron Price Performance

Shares of Longeveron stock opened at $2.20 on Friday. Longeveron has a one year low of $0.77 and a one year high of $23.90. The business’s 50 day simple moving average is $2.03 and its two-hundred day simple moving average is $2.10. The stock has a market capitalization of $31.59 million, a P/E ratio of -0.25 and a beta of 0.36.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LGVN shares. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Longeveron in a research report on Monday, November 4th. Maxim Group reduced their price target on Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 27th.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.